Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

272 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.
Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL. Comer SD, et al. Among authors: cone e. Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19. Pain. 2012. PMID: 22998781 Free PMC article.
An iterative model for in vitro laboratory assessment of tamper deterrent formulations.
Cone EJ, Giordano J, Weingarten B. Cone EJ, et al. Drug Alcohol Depend. 2013 Jul 1;131(1-2):100-5. doi: 10.1016/j.drugalcdep.2012.12.006. Epub 2013 Jan 17. Drug Alcohol Depend. 2013. PMID: 23332441
Rapid absorption of nicotine from new nicotine gum formulations.
Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T. Shiffman S, et al. Among authors: cone ej. Pharmacol Biochem Behav. 2009 Jan;91(3):380-4. doi: 10.1016/j.pbb.2008.08.012. Epub 2008 Aug 16. Pharmacol Biochem Behav. 2009. PMID: 18762208 Clinical Trial.
Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing.
Altomare C, Kinzler ER, Buchhalter AR, Cone EJ, Costantino A. Altomare C, et al. Among authors: cone ej. J Opioid Manag. 2017 Nov/Dec;13(6):441-448. doi: 10.5055/jom.2017.0420. J Opioid Manag. 2017. PMID: 29308590 Review.
The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.
Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM. Cone EJ, et al. Am J Drug Alcohol Abuse. 2017 May;43(3):291-298. doi: 10.1080/00952990.2016.1278006. Epub 2017 Feb 13. Am J Drug Alcohol Abuse. 2017. PMID: 28448223
Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
Webster LR, Markman J, Cone EJ, Niebler G. Webster LR, et al. Among authors: cone ej. Postgrad Med. 2017 Jan;129(1):102-110. doi: 10.1080/00325481.2017.1268902. Epub 2016 Dec 12. Postgrad Med. 2017. PMID: 27915497 Review.
Behavioral economic demand metrics for abuse deterrent and abuse potential quantification.
Schwartz LP, Roma PG, Henningfield JE, Hursh SR, Cone EJ, Buchhalter AR, Fant RV, Schnoll SH. Schwartz LP, et al. Among authors: cone ej. Drug Alcohol Depend. 2019 May 1;198:13-20. doi: 10.1016/j.drugalcdep.2019.01.022. Epub 2019 Feb 27. Drug Alcohol Depend. 2019. PMID: 30861390
272 results
Jump to page
Feedback